Leukaemia

Oncology·MeSH: Leukemia

Prevalence

30.4 / 100K

Incidence

7.5 / 100K/yr

14 drugs in development·6 companies·1 clinical trial

Drug Pipeline by Phase

Phase 3(4)

Drug	Company
azd3632	ASTRAZENECA PLC (AZN)
olverembatinib	CHINA PHARMA HOLDINGS, INC. (CPHI)
Surovatamig	ASTRAZENECA PLC (AZN)
vincristine	ASTRAZENECA PLC (AZN)

Phase 1(6)

Drug	Company
fludarabine	Sanofi (SNY)
fludarabine	Sanofi (SNYNF)
lisaftoclax	ASCENTAGE PHARMA GROUP INTERNATIONAL (AAPG)
olverembatinib	ASCENTAGE PHARMA GROUP INTERNATIONAL (AAPG)
sar445419	Sanofi (SNYNF)
sar445419	Sanofi (SNY)

Phase 1/Phase 2(3)

Drug	Company
reduced-dose hht	ASCENTAGE PHARMA GROUP INTERNATIONAL (AAPG)
sar443579	Sanofi (SNY)
standard-dose hht	ASCENTAGE PHARMA GROUP INTERNATIONAL (AAPG)

Phase 2/Phase 3(1)

Drug	Company
liposomal annamycin injection in combination with cytarabine	Moleculin Biotech, Inc. (MBRX)

BioSniper tracks 14 drugs in development for Leukaemia across 6 companies.

There are 1 clinical trial targeting Leukaemia tracked by BioSniper.

The estimated prevalence of Leukaemia is approximately 30.4 per 100,000 population.

Full trial data, competitive analysis, and AI-powered pipeline tracking.